Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $69.2 million, representing a growth of 55% compared to Q1 2024 [7][29] - Gross margin for Q1 2025 was 63.9%, consistent with Q4 2024 and up 750 basis points year-over-year [35] - Net loss for Q1 2025 was $24.7 million, compared to a net loss of $26 million in the same period of the prior year [37] Business Line Data and Key Metrics Changes - US revenue for Q1 2025 was $60.3 million, representing a growth of 50% compared to the prior year [29] - The company sold 43 robotic systems in Q1 2025, with an average selling price of approximately $435,000 [31] - US handpiece revenue for Q1 2025 was $38 million, representing a growth of 61% year-over-year, with 11,235 handpieces sold [33] Market Data and Key Metrics Changes - International revenue in Q1 2025 was $8.9 million, representing growth of 104% compared to the prior year, primarily driven by strong sales in the UK [26][34] - The US installed base of robotic systems reached 547, reflecting a growth of 55% compared to the prior year [8] Company Strategy and Development Direction - The company is focused on expanding the installed base of Hydro systems in greenfield accounts while also seeing interest from existing customers for replacements [39] - The management believes that the current tariff environment will not compromise the path to achieving long-term profitability objectives [44] - The company aims to standardize aquablation therapy across hospital networks, driven by consistent outcomes and operational efficiency [22][112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to continue growing the installed base and procedural volumes despite macroeconomic challenges [25] - The company anticipates a modest impact on 2025 gross margin due to strong inventory positions and limited exposure to foreign suppliers [11][53] - Management highlighted the positive changes in Medicare coverage that will expand access to aquablation therapy [15][126] Other Important Information - The company is preparing for the AUA conference, where it will present significant clinical data related to aquablation therapy [47][49] - The management is actively evaluating operational strategies to mitigate future tariff exposure [44][102] Q&A Session Summary Question: Can you discuss the CapEx environment and buyer interest in the system? - Management has not seen an impact on capital interest in acquiring Hydro systems, with a strong pipeline and high hospital interest [59][60] Question: How many handpieces sold in Q1 were pushed from Q4? - The impact from deferrals in Q4 was largely offset by the saline issue, resulting in Q1 procedures driven by business strength [66] Question: Can you provide more color on procedure volume growth in March? - March showed a return to normalcy, with guidance for Q2 and Q3 assuming similar utilization rates to Q1 [71][72] Question: What is the current utilization in IDN accounts? - Utilization is driven by surgeons, with IDNs showing interest in educating staff to increase patient volume for aquablation [108][110] Question: How is the company balancing growth in OUS markets? - The company is focusing on the UK as a key market while ensuring disciplined growth strategies [86][87] Question: What are the implications of the recent LCD changes? - The removal of certain limitations will streamline patient pre-workup and expand access to aquablation therapy [126][128]

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance "We began 2025 with strong performance, delivering total revenue growth of 55% in the first quarter. Procedural momentum remained robust heading into the second quarter, reinforcing our confidence that the saline disruption is behind us and that we are well-positioned for another year of strong procedure growth," said Reza Zadno, Chief Executive Officer. "The U.S. launch of our Hydros™ system continues to bu ...

SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for t ...

SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure y ...

Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trialSAN JOSE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced its Aquablation therapy was evaluated in the indepe ...

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics’ management team presenting include: Reza ...

The mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companies, offering the Seeking Alpha investor compelling points of view on these often overlooked investment opportunities; and periodically identifying potential opportunities in large- and mega-cap companies, expanding the scope to provide encompassing coverage ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-K ___________________________________ (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-04321 ___________________ ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $68.2 million, representing a growth of 57% compared to Q4 2023 [7] - Full year total revenue was $224.5 million, indicating a growth of 65% [8] - Gross margin for Q4 2024 reached 64%, marking an all-time high [36] - Net loss for Q4 2024 was $18.9 million, an improvement from $27.5 million in the same period of the prior year [40] - Adjusted EBITDA loss was $10.3 million compared to a loss of $23.3 million in Q4 2023 [40] Business Line Data and Key Metrics Changes - The company sold 60 new robotic systems in Q4 2024, with over 95% being HYDROS systems at an average selling price of approximately $460,000 [20][33] - US handpiece and consumable revenue for Q4 2024 was $29.3 million, representing a growth of 36% compared to Q4 2023 [34] - International revenue in Q4 2024 was $7.8 million, showing a growth of 137% compared to the prior year period [35] Market Data and Key Metrics Changes - The US installed base of robotic systems grew to 505, a 60% increase year-over-year [8] - Approximately 50% of all BPH resective surgeries are Medicare, with the other half being private pay [23] Company Strategy and Development Direction - The company aims to transform the global treatment of BPH and become the standard of care, currently holding about 10% US BPH resective market share [9] - The introduction of the HYDROS Robotic System and FirstAssist AI is expected to enhance procedural accuracy and outcomes [11][12] - The company is pursuing a pivotal randomized clinical study for prostate cancer, which could position Aquablation therapy as a first-line surgical treatment [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in procedure volumes following a saline supply shortage that impacted Q4 2024 [28][30] - The company anticipates full year 2025 total revenue to be approximately $320 million, representing growth of about 43% compared to 2024 [41] - Management highlighted the importance of strategic investments to drive long-term growth, particularly in clinical trials [48] Other Important Information - The company experienced a saline supply shortage due to Hurricane Helene, which resulted in a delay or cancellation of 10% to 20% of expected procedures in Q4 [26][28] - The company has a strong cash position with $337 million in cash, cash equivalents, and restricted cash as of December 31 [40] Q&A Session Summary Question: Impact of saline shortage on procedures - Management estimated that the saline shortage resulted in a delay or cancellation of up to 2,000 procedures in Q4, based on customer surveys and internal analysis [67][70] - Accounts not impacted by the saline shortage performed as expected, showing strong sequential growth [76] Question: Q1 utilization growth - Q1 guidance does not fully assume that all lost procedures from Q4 will return, but there is optimism for recovery in February and March [80][81] Question: HYDROS feedback and account mix - Customers are excited about the HYDROS features, with 95% of procedures utilizing the FirstAssist AI [102] - There is a growing demand from medium and low-volume BPH hospitals for Aquablation systems [106] Question: Replacement revenue and ASP - Replacement ASPs for AquaBeam customers are expected to be lower, around $50,000 to $100,000, while future replacements will align more closely with greenfield sales [128][129] - The $3 million in anticipated replacement revenue is separate from the guidance for new systems [135]